Study design and population
This cohort study retrospectively collected the data of all women aged 38–46 years who underwent their first OS cycle scheduled for PGT-A in Shanghai JiAi Genetics and IVF Institute from January 2021 to June 2022 in the institutional electronic database. Each participant was required to have a body mass index (BMI) in the normal range (18.50–24.0 kg/mThe women included were offered GH or not during OS at the discretion of the attending physicians or subject to the wishes of the couple after extensive counseling. Patients in the GH group received 4 IU/day subcutaneous rh-GH (Saizen, Changchun GeneScience, Changchun, China) from the beginning of OS to the trigger day, which was a routine dosage of GH supplementation in our IVF center and was also suggested by other studies [The study protocol was approved by the Research Ethics Committee of the Shanghai JiAi Genetics and IVF Institute (Approval Number: JIAI E2022-14, Study ID: JIAI E2022-022, NCT05574894, 